The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | Optimizing treatment strategies for neuroendocrine carcinomas
Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, comments on the challenges of determining the optimal treatment approach for neuroendocrine carcinomas, highlighting the need for a clear control arm in studies to inform adjuvant or neoadjuvant treatment decisions. Dr O’Connor emphasizes the importance of considering the origin of the primary tumor and the patient’s clinical situation when selecting a surgical approach. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
One of the problems, the evidence in this setting is that we have no clear control arm in different studies. So probably the NEONEC study, this is a study led by the HERCO group, probably will see some answer in terms of the adjuvant or neoadjuvant because in the literature it’s not easy to understand how the neoadjuvant, adjuvant or perioperative treatment is in terms of the treatment...
One of the problems, the evidence in this setting is that we have no clear control arm in different studies. So probably the NEONEC study, this is a study led by the HERCO group, probably will see some answer in terms of the adjuvant or neoadjuvant because in the literature it’s not easy to understand how the neoadjuvant, adjuvant or perioperative treatment is in terms of the treatment. But the key takeaway of my presentation was that depending on the origin of the primary tumor, depending on the clinical situation of the patient, it is important that the surgical approach, even in more localized disease, and also considering systemic therapy and radiation therapy depending on the location. For example, esophageal, anal canal, or rectal cancer. That’s a very good example of trimodality in terms of the neuroendocrine carcinoma in this setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
